

treatment group. There were 15 cases excluded and 35 cases remained in the control group. The treatment group was given *Pingwei Capsules* (4 caps once and three times daily). The control group was given Vitacoenzyme Tablets (4 tablets once and three times daily). The treatment lasted for 6 months. The symptoms, gastroscopy results and the expressions of vascular endothelial growth factor (VEGF) and CDX2 were observed before and after treatment in both groups. **Results** The total effective rate of the treatment group and control group was 91.1% and 77.1% respectively, with a significant difference between groups ($P < 0.05$). After treatment, the symptom scores were significantly decreased in both groups ($P < 0.05$), especially in the treatment group ($P < 0.05$). The pathological improvement rate in the treatment group and control group was 51.1% and 31.4% respectively, with a significant difference between groups ($P < 0.05$). After treatment, the improvement rates of erosion, mucosal Shirai, particle hyperplasia, vascular permeability and bile reflux in the treatment group were superior to those in the control group ($P < 0.05$). The expression of VEGF was significantly decreased after treatment in both groups ($P < 0.05$). There was no significant difference between groups in the expression rate of VEGF ($P > 0.05$). After treatment, the positive expression rate of CDX2 in type I intestinal metaplasia (IM), type II IM and dysplasia was significantly decreased in the treatment group ($P < 0.01$). After treatment, the positive expression rate of CDX2 in type I IM and type II IM was significantly decreased in the control group ($P < 0.01$). After treatment, the positive expression rate of CDX2 in type I IM and type II IM in the treatment group was significantly lower than that in the control group ($P < 0.05$). **Conclusion** *Pingwei Capsules* can effectively relieve the symptoms and pathological changes of PLGC patients, promote the expression of VEGF, improve gastric blood circulation, strengthen and repair the mucosal regeneration, inhibit the expression of CDX2 and reverse precancerous lesions.

Keywords *Pingwei Capsules*; chronic atrophic gastritis; precancerous lesions; intestinal metaplasia; dysplasia; vascular endothelial growth factor; gut-specific transcription factor

(收稿日期: 2014-02-25; 修回日期: 2014-07-08)

[编辑: 王利芬]

颈复康颗粒、腰痛宁胶囊、蚁参蠲痹胶囊临床研究与应用征文通知

山庄牌“颈复康颗粒”、“腰痛宁胶囊”、“蚁参蠲痹胶囊”系颈复康药业集团有限公司生产的治疗颈椎病、腰腿痛、类风湿性关节炎的常用药品,因其疗效好、价格低,深受患者与医生的信赖。为了总结“颈复康颗粒”、“腰痛宁胶囊”、“蚁参蠲痹胶囊”多年来的临床应用经验,更好地指导临床用药,中医杂志社与颈复康药业集团有限公司联合举办此次征文活动,现将有关事项通知如下。

1. 征文内容:(1)“颈复康颗粒”治疗各种类型颈椎病(神经根型、椎动脉型、交感神经型、颈型、混合型等)的临床应用经验、体会与分析“腰痛宁胶囊”治疗腰椎间盘突出症、坐骨神经痛、腰肌劳损、腰肌纤维炎、风湿性关节痛,症见腰腿痛、关节痛及肢体活动受限等病症的临床经验、体会与分析“蚁参蠲痹胶囊”治疗风湿性关节炎、类风湿性关节炎、强直性脊柱炎、骨关节炎、坐骨神经痛、肩周炎、痛风、系统性红斑狼疮等病症的临床经验、体会与分析。(2)“颈复康颗粒”、“腰痛宁胶囊”、“蚁参蠲痹胶囊”临床用量、用法的研究与经验总结;(3)“颈复康颗粒”、“腰痛宁胶囊”、“蚁参蠲痹胶囊”组方研究、药理研究与探讨;(4)“颈复康颗粒”、“腰痛宁胶囊”、“蚁参蠲痹胶囊”临床扩大应用范围的研究与探讨。2. 征文要求:(1)来稿应未公开发表,字数在4000字以内,请加盖单位公章,不退稿;(2)请采用法定计量单位;(3)文题下署作者姓名、单位、通讯地址、邮编和联系电话等。请用电子邮件形式投稿(Word文件格式)。3. 奖励办法:由全国中医药界知名专家组成评审委员会,将评选出:一等奖2篇(每篇奖励5000元);二等奖8篇(每篇奖励3000元);三等奖15篇(每篇奖励1500元);优秀奖25篇(每篇奖励价值500元礼品)。获奖者将由主办单位颁发获奖论文证书、奖金或礼品,获奖论文达到刊用标准者将在《中医杂志》等期刊发表,其他获奖论文将在《中医杂志》2015年增刊发表,并赠送样刊1册。此次征文活动不收任何费用。评选结果将在《中医杂志》、《健康报》上予以公布。

主办单位将邀请部分获奖论文作者免费参加在河北省承德市召开的颁奖大会并考察承德颈复康药业集团有限公司。论文请于2015年3月30日前发至邮箱:jtcn@163.com。联系地址:北京东直门内南小街16号中医杂志社,联系人:22号编辑,邮编:100700。电话:(010)64035632。